30.01.19: Start of Quiet Period
Start of Quiet PeriodLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 28, 2019 Category: Pharmaceuticals Source Type: news
16.01.19: Roadshow Melbourne
Roadshow MelbourneLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 15, 2019 Category: Pharmaceuticals Source Type: news
17.01.19: Roadshow Sydney
Roadshow SydneyLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 15, 2019 Category: Pharmaceuticals Source Type: news
15.01.19: Roadshow Singapore
Roadshow SingaporeLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 14, 2019 Category: Pharmaceuticals Source Type: news
14.01.19: Commerzbank German Investment Seminar 2019, New York
Commerzbank German Investment Seminar 2019, New YorkLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 13, 2019 Category: Pharmaceuticals Source Type: news
26.02.19: Announcement of proposed dividend
Announcement of proposed dividendLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 10, 2019 Category: Pharmaceuticals Source Type: news
08.01.19: New predictive seed placement technology delivers strong results in 2018:
Bayer expands digital innovation pipeline at The Climate Corporation to bring breakthrough digital tools to more farmersmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 8, 2019 Category: Pharmaceuticals Source Type: news
20.12.18: Not intended for U.S. and UK Media
Bayer receives approval in China for endometriosis treatment Visanne™mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - December 20, 2018 Category: Pharmaceuticals Source Type: news
02.05.19: Planned dividend payment day
Planned dividend payment dayLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - December 19, 2018 Category: Pharmaceuticals Source Type: news
18.12.18: Bayer extends credit line and increases volume to 4.5 billion euros
Bayer extends credit line and increases volume to 4.5 billion eurosmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - December 18, 2018 Category: Pharmaceuticals Source Type: news
05.12.18: Capital Markets Day 2018
Bayer to drive value creation as company pursues ambitious growth targets through 2022Company strongly positioned to benefit from key megatrends / Through 2022, Bayer aims to grow sales by 4 percent, EBITDA before special items by 9 percent and free cash flow by 18 percent annually on average / Adjusted EBITDA margin targets for 2022: Crop Science to exceed 30 percent, Pharmaceuticals to hit more than 35 percent, and Consumer Health to reach approximately 24 percentmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - December 5, 2018 Category: Pharmaceuticals Source Type: news
29.11.18: Group to take comprehensive range of portfolio, efficiency and structural measures
Bayer to strengthen core life science businesses while significantly enhancing productivity and profitabilityGroup plans to exit Animal Health business, the Consumer Health brands Coppertone™ and Dr. Scholl's™, and sell its 60-percent interest in Currenta, a site services provider in Germany / Efficiency and structural measures set to enhance competitiveness and generate annual contributions of 2.6 billion euros as of 2022 including the expected synergies from the Monsanto acquisition / A portion of the contributions to be reinvested in core businesses / Total one-time costs expected at a factor of 1.7 times an...
Source: Bayer IR Newsfeed: Events - November 29, 2018 Category: Pharmaceuticals Source Type: news
27.11.18: Not intended for U.S. and UK Media
Bayer receives EU approval for its hemophilia A treatment Jivi®The safety and efficacy profile of Jivi has been demonstrated in more than five years of clinical studies / Prophylaxis with Jivi enables sustained factor VIII concentrations in the blood over timemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 27, 2018 Category: Pharmaceuticals Source Type: news
27.11.18: Not intended for U.S. and UK Media
U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusionFirst treatment with a tumor-agnostic indication at the time of initial FDA approval / Larotrectinib approved under the brand name Vitrakvi® / 75% overall response rate (ORR) (95% CI, 61%, 85%) [22% complete response (CR) and 53% partial response (PR)] across various solid tumors in adults and children / Adverse events (AEs) of any grade observed in more than 20 percent of patients, regardless of attribution, included increased ALT (45%), increased AST (45%), anemia (42%), fatigue (37%), nausea (2...
Source: Bayer IR Newsfeed: Events - November 27, 2018 Category: Pharmaceuticals Source Type: news
25.04.19: Q1 2019 Quarterly Statement
Q1 2019 Quarterly StatementLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 13, 2018 Category: Pharmaceuticals Source Type: news
